These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 29692317)
1. Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018. Knol MJ; Ruijs WL; Antonise-Kamp L; de Melker HE; van der Ende A Euro Surveill; 2018 Apr; 23(16):. PubMed ID: 29692317 [TBL] [Abstract][Full Text] [Related]
2. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination. van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167 [TBL] [Abstract][Full Text] [Related]
3. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial. van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575 [TBL] [Abstract][Full Text] [Related]
4. Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study. Ohm M; Hahné SJM; van der Ende A; Sanders EAM; Berbers GAM; Ruijs WLM; van Sorge NM; de Melker HE; Knol MJ Clin Infect Dis; 2022 Jul; 74(12):2173-2180. PubMed ID: 34525199 [TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia. Ilyina N; Kharit S; Namazova-Baranova L; Asatryan A; Benashvili M; Tkhostova E; Bhusal C; Arora AK Hum Vaccin Immunother; 2014; 10(8):2471-81. PubMed ID: 25424958 [TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine. Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132 [TBL] [Abstract][Full Text] [Related]
7. Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine. van Ravenhorst MB; den Hartog G; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM PLoS One; 2018; 13(4):e0191261. PubMed ID: 29672552 [TBL] [Abstract][Full Text] [Related]
8. Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States. Mbaeyi S; Pondo T; Blain A; Yankey D; Potts C; Cohn A; Hariri S; Shang N; MacNeil JR JAMA Pediatr; 2020 Sep; 174(9):843-851. PubMed ID: 32687590 [TBL] [Abstract][Full Text] [Related]
9. Need for Optimisation of Immunisation Strategies Targeting Invasive Meningococcal Disease in the Netherlands. Bousema JC; Ruitenberg J Int J Health Policy Manag; 2015 Sep; 4(11):757-61. PubMed ID: 26673336 [TBL] [Abstract][Full Text] [Related]
10. Seroprevalence of meningococcal ACWY antibodies across the population in the Netherlands: Two consecutive surveys in 2016/17 and 2020. Ohm M; Knol MJ; Vos ERA; Bogaard MJM; van Rooijen DM; Sanders EAM; de Melker HE; van der Klis FRM; Berbers GAM Vaccine; 2022 Jan; 40(1):59-66. PubMed ID: 34839991 [TBL] [Abstract][Full Text] [Related]
11. A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination. Bijlsma MW; Brouwer MC; Spanjaard L; van de Beek D; van der Ende A Clin Infect Dis; 2014 Nov; 59(9):1216-21. PubMed ID: 25069869 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. Snape MD; Perrett KP; Ford KJ; John TM; Pace D; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ JAMA; 2008 Jan; 299(2):173-84. PubMed ID: 18182599 [TBL] [Abstract][Full Text] [Related]
13. Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers. Vesikari T; Borrow R; Da Costa X; Thomas S; Eymin C; Boisnard F; Lockhart S Vaccine; 2018 Dec; 36(52):8019-8027. PubMed ID: 30471953 [TBL] [Abstract][Full Text] [Related]
14. Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling study. Campbell H; Andrews N; Parikh SR; White J; Edelstein M; Bai X; Lucidarme J; Borrow R; Ramsay ME; Ladhani SN Lancet Child Adolesc Health; 2022 Feb; 6(2):96-105. PubMed ID: 34883094 [TBL] [Abstract][Full Text] [Related]
15. An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine. Keshavan P; Pellegrini M; Vadivelu-Pechai K; Nissen M Expert Rev Vaccines; 2018 Oct; 17(10):865-880. PubMed ID: 30198805 [TBL] [Abstract][Full Text] [Related]
16. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy. Pace D Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410 [TBL] [Abstract][Full Text] [Related]
17. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers. McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636 [TBL] [Abstract][Full Text] [Related]
18. [Meningococcal vaccines: from polysaccharide to conjugate vaccines]. Cohen R; Levy C Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of a single dose of the quadrivalent meningococcal conjugate vaccine, MenACWY-CRM, in the Korean Armed Forces. Im JH; Woo H; Ha BM; Lee JS; Chung MH; Jung J Vaccine; 2020 Jan; 38(4):730-732. PubMed ID: 31787413 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines. Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM Pediatr Infect Dis J; 2015 Dec; 34(12):e298-307. PubMed ID: 26780033 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]